ADC Therapeutics SA annual depreciation and amortization
2018
2019
2020
2021
2022
2023
2024
2025
ADC Therapeutics SA Depreciation & Amortization Growth & History (ADCT)
ADC Therapeutics SA's depreciation and amortization was $705,000 for fiscal 2025.
View full ADC Therapeutics SA company overviewADC Therapeutics SA annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $705,000 | −$629,000 | −47.15% |
| 2024 | 2024-12-31 | $1.3M | $147,000 | +12.38% |
| 2023 | 2023-12-31 | $1.2M | $170,000 | +16.72% |
| 2022 | 2022-12-31 | $1.0M | $97,000 | +10.54% |
| 2021 | 2021-12-31 | $920,000 | $146,000 | +18.86% |
| 2020 | 2020-12-31 | $774,000 | $222,000 | +40.22% |
| 2019 | 2019-12-31 | $552,000 | $64,000 | +13.11% |
| 2018 | 2018-12-31 | $488,000 | — | — |
ADC Therapeutics SA quarterly depreciation and amortization
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $114,000 | −$228,000 | −66.67% |
| Q4 2025 | 2025-12-31 | $113,000 | — | — |
| Q3 2025 | 2025-09-30 | $0 | −$336,000 | — |
| Q2 2025 | 2025-06-30 | $362,000 | $36,000 | +11.04% |
| Q1 2025 | 2025-03-31 | $342,000 | $11,000 | +3.32% |
| Q3 2024 | 2024-09-30 | $336,000 | $20,000 | +6.33% |
| Q2 2024 | 2024-06-30 | $326,000 | $53,000 | +19.41% |
| Q1 2024 | 2024-03-31 | $331,000 | $68,000 | +25.86% |
| Q3 2023 | 2023-09-30 | $316,000 | — | — |
| Q2 2023 | 2023-06-30 | $273,000 | — | — |
| Q1 2023 | 2023-03-31 | $263,000 | — | — |
ADC Therapeutics SA depreciation and amortization trends
Over the last five fiscal years, ADC Therapeutics SA's depreciation and amortization decreased from $774,000 to $705,000, a change of −$69,000. The latest reported quarter, Q1 2026, shows $114,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ADC Therapeutics SA source filings ↗